Vuity is a drug owned by Abbvie Inc. It is protected by 2 US drug patents filed from 2021 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 24, 2039. Details of Vuity's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11285134 | Presbyopia treatments |
Apr, 2039
(14 years from now) | Active |
| US10610518 | Presbyopia treatments |
Apr, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vuity's patents.
Latest Legal Activities on Vuity's Patents
Given below is the list of recent legal activities going on the following patents of Vuity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Sep, 2023 | US10610518 |
| Recordation of Patent Grant Mailed Critical | 29 Mar, 2022 | US11285134 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Mar, 2022 | US11285134 |
| Email Notification Critical | 10 Mar, 2022 | US11285134 |
| Issue Notification Mailed Critical | 09 Mar, 2022 | US11285134 |
| Dispatch to FDC | 01 Mar, 2022 | US11285134 |
| Mail Post Card | 23 Feb, 2022 | US11285134 |
| Issue Fee Payment Verified Critical | 17 Feb, 2022 | US11285134 |
| Issue Fee Payment Received Critical | 17 Feb, 2022 | US11285134 |
| Email Notification Critical | 15 Feb, 2022 | US11285134 |
FDA has granted several exclusivities to Vuity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vuity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vuity.
Exclusivity Information
Vuity holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Vuity's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2024 |
| New Dosing Schedule(D-187) | Mar 28, 2026 |
Several oppositions have been filed on Vuity's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Vuity's generic, the next section provides detailed information on ongoing and past EP oppositions related to Vuity patents.
Vuity's Oppositions Filed in EPO
Vuity has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 20, 2022, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP19729883A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19729883A | Dec, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Vuity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vuity's family patents as well as insights into ongoing legal events on those patents.
Vuity's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vuity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 24, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vuity Generic API suppliers:
Pilocarpine Hydrochloride is the generic name for the brand Vuity. 8 different companies have already filed for the generic of Vuity, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vuity's generic
How can I launch a generic of Vuity before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Vuity's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Vuity's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Vuity -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.0125 | 30 Dec, 2022 | 1 | 24 Apr, 2039 |
Alternative Brands for Vuity
Vuity which is used for treating presbyopia in adults., has several other brand drugs using the same active ingredient (Pilocarpine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Alcon |
| |
| Orasis Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Pilocarpine Hydrochloride, Vuity's active ingredient. Check the complete list of approved generic manufacturers for Vuity
About Vuity
Vuity is a drug owned by Abbvie Inc. It is used for treating presbyopia in adults. Vuity uses Pilocarpine Hydrochloride as an active ingredient. Vuity was launched by Abbvie in 2021.
Approval Date:
Vuity was approved by FDA for market use on 28 October, 2021.
Active Ingredient:
Vuity uses Pilocarpine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Pilocarpine Hydrochloride ingredient
Treatment:
Vuity is used for treating presbyopia in adults.
Dosage:
Vuity is available in solution form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.25% | SOLUTION | Prescription | OPHTHALMIC |